These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11893750)

  • 61. p63.
    Little NA; Jochemsen AG
    Int J Biochem Cell Biol; 2002 Jan; 34(1):6-9. PubMed ID: 11733180
    [TBL] [Abstract][Full Text] [Related]  

  • 62. p63 and p73 in human cancer: defining the network.
    Deyoung MP; Ellisen LW
    Oncogene; 2007 Aug; 26(36):5169-83. PubMed ID: 17334395
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes.
    Khokhar SK; Kommagani R; Kadakia MP
    Cell Res; 2008 Oct; 18(10):1061-73. PubMed ID: 18626511
    [TBL] [Abstract][Full Text] [Related]  

  • 64. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.
    Yang A; Kaghad M; Wang Y; Gillett E; Fleming MD; Dötsch V; Andrews NC; Caput D; McKeon F
    Mol Cell; 1998 Sep; 2(3):305-16. PubMed ID: 9774969
    [TBL] [Abstract][Full Text] [Related]  

  • 65. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.
    Flores ER; Tsai KY; Crowley D; Sengupta S; Yang A; McKeon F; Jacks T
    Nature; 2002 Apr; 416(6880):560-4. PubMed ID: 11932750
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Redox state of p63 and p73 core domains regulates sequence-specific DNA binding.
    Tichý V; Navrátilová L; Adámik M; Fojta M; Brázdová M
    Biochem Biophys Res Commun; 2013 Apr; 433(4):445-9. PubMed ID: 23501101
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The dominant-negative interplay between p53, p63 and p73: A family affair.
    Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
    Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DNA-binding and transactivation activities are essential for TAp63 protein degradation.
    Ying H; Chang DL; Zheng H; McKeon F; Xiao ZX
    Mol Cell Biol; 2005 Jul; 25(14):6154-64. PubMed ID: 15988026
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas.
    Chen YK; Huse SS; Lin LM
    Clin Otolaryngol Allied Sci; 2003 Oct; 28(5):451-5. PubMed ID: 12969350
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.
    Flores ER; Sengupta S; Miller JB; Newman JJ; Bronson R; Crowley D; Yang A; McKeon F; Jacks T
    Cancer Cell; 2005 Apr; 7(4):363-73. PubMed ID: 15837625
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Monoclonal antibodies raised against Xenopus p53 interact with human p73.
    Le Bras M; Delattre V; Bensaad K; Blandino G; Soussi T
    Oncogene; 2002 Feb; 21(8):1304-8. PubMed ID: 11850851
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?
    Crook T; Nicholls JM; Brooks L; O'Nions J; Allday MJ
    Oncogene; 2000 Jul; 19(30):3439-44. PubMed ID: 10918601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. p63 and p73 transactivate differentiation gene promoters in human keratinocytes.
    De Laurenzi V; Rossi A; Terrinoni A; Barcaroli D; Levrero M; Costanzo A; Knight RA; Guerrieri P; Melino G
    Biochem Biophys Res Commun; 2000 Jun; 273(1):342-6. PubMed ID: 10873608
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.
    Hagiwara K; McMenamin MG; Miura K; Harris CC
    Cancer Res; 1999 Sep; 59(17):4165-9. PubMed ID: 10485447
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.
    Uramoto H; Izumi H; Nagatani G; Ohmori H; Nagasue N; Ise T; Yoshida T; Yasumoto K; Kohno K
    Biochem J; 2003 Apr; 371(Pt 2):301-10. PubMed ID: 12534345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression.
    Senoo M; Matsumura Y; Habu S
    Oncogene; 2002 Apr; 21(16):2455-65. PubMed ID: 11971180
    [TBL] [Abstract][Full Text] [Related]  

  • 77. p53FamTaG: a database resource of human p53, p63 and p73 direct target genes combining in silico prediction and microarray data.
    Sbisà E; Catalano D; Grillo G; Licciulli F; Turi A; Liuni S; Pesole G; De Grassi A; Caratozzolo MF; D'Erchia AM; Navarro B; Tullo A; Saccone C; Gisel A
    BMC Bioinformatics; 2007 Mar; 8 Suppl 1(Suppl 1):S20. PubMed ID: 17430565
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism.
    Serber Z; Lai HC; Yang A; Ou HD; Sigal MS; Kelly AE; Darimont BD; Duijf PH; Van Bokhoven H; McKeon F; Dötsch V
    Mol Cell Biol; 2002 Dec; 22(24):8601-11. PubMed ID: 12446779
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1.
    Zhang J; Sun W; Kong X; Zhang Y; Yang HJ; Ren C; Jiang Y; Chen M; Chen X
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24259-24267. PubMed ID: 31712410
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P63 in health and cancer.
    Gonfloni S; Caputo V; Iannizzotto V
    Int J Dev Biol; 2015; 59(1-3):87-93. PubMed ID: 26374530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.